Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
Strategies For The Bursting Bond Bubble

2018-07-11 seekingalpha
This year’s increased stock market volatility and sharp declines in the emerging markets are the result of rising interest rates. If interest rates revert to the normal 2007 pre-financial crisis levels, a process not even halfway complete, the potential for significant declines in equity, bond and real estate markets becomes a serious and present risk. This letter will address ways to help preserve your wealth if rising interest rates trigger significant market declines.
AMID CLMT SXE

0
Calumet Specialty Products Heading Dramatically Higher

2018-07-10 seekingalpha
Calumet is in the middle of an extraordinary turnaround, which has been recently masked by the effects of Hurricane Harvey and a botched computer (ERP) implementation.
MS.PRI CLMT MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

0
Husky awaits explosion investigation results before restarting asphalt refinery

2018-07-04 cbc.ca
Two months after fire and explosions ripped through its recently purchased asphalt refinery in Superior, Wis., Husky Energy Inc. says it still doesn't know when it will be able to restart the facility.
HSE CLMT HUSKF

12
Calumet Specialty (CLMT) Presents At BMO Capital Markets Chemicals Conference - Slideshow

2018-06-26 seekingalpha
The following slide deck was published by Calumet Specialty Products Partners, L.P. in conjunction with this event.
CLMT

17
Ferrellgas Partners (FGP) Lags Q3 Earnings, Sales Estimates

2018-06-07 zacks
Ferrellgas Partners LP (FGP - Free Report) reported third-quarter fiscal 2018 adjusted earnings of 18 cents per unit, missing the Zacks Consensus Estimate of 26 cents by 30.8%. Total Revenues In the reported quarter, Ferrellgas Partners’ total revenues were $515.8 million, missing the Zacks Consensus Estimate of $621 million by 17%. The top line also declined 4.1% from $538 million in the prior-year quarter.
SRLP CLMT SUN FGP

12
Calumet Specialty Products Partners (CLMT) Presents At Bank of America Merrill Lynch Energy Credit Conference - Slideshow

2018-06-06 seekingalpha
The following slide deck was published by Calumet Specialty Products Partners, L.P. in conjunction with this event.
CLMT

27
Top MLP Gainers in the Week Ending June 1

2018-06-06 marketrealist
Calumet Specialty Products Partners (CLMT), an MLP involved in the production of specialty fuels and other refined products, was the top MLP gainer in the week ending June 1. Calumet Specialty Products Partners rallied 23.9%. Last week, the gains could have been due to strong refined products demand during Memorial Day weekend and the start of the summer driving season. Calumet Specialty Products Partners has traded in the green for 2018 following last week’s rally.
NGL LGCYP LGCYO CLMT NGL.PRB ENLK ENLC CEQP NS.PRC NS.PRB NSH LGCY CVRR ENBL NS NS.PRA

90
CLMT / Calumet Specialty Products Partners, L.P. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-22 fintel.io
Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) has 123 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 22,354,921 shares. Largest shareholders include Heritage Group, Morgan Stanley, Susquehanna International Group, Llp, Susquehanna International Group, Llp, Knott David M, Goldman Sachs Group Inc, Adams Asset Advisors, LLC, Adams Asset Advisors, LLC, Royal Bank Of Canada, and Deutsche Bank Ag\.
DB XOM GS.PRB MS.PRE GS.PRA MS.PRF RY.PRSCL MS.PRG RBCDF HUSKF MS.PRA HSE GS GLSSP MS JBK RY CLMT GSC GS.PRICL TFG GSJ GS.PRJ GS.PRI RY MS.PRI GS.PRD MS.PRK CVX GS.PRC RY.PRS GJS GS.PRN RY.PRT GS.PRK

12
Calumet Specialty Products Partners' (CLMT) CEO Timothy Go on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) Q1 2018 Results Earnings Conference Call May 16, 2018 9:00 AM ET
CLMT

12
Calumet Specialty Products Partners, L.P. 2018 Q1 - Results - Earnings Call Slides

2018-05-16 seekingalpha
The following slide deck was published by Calumet Specialty Products Partners, L.P. in conjunction with their 2018 Q1 earnings call.
CLMT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CLMT / Calumet Specialty Products Partners, L.P. on message board site Silicon Investor.

Claremont Technology Group (CLMT)
CUSIP: 131476103